Hanmi Pharm Launches Neutropenia Treatment 'Rolontis' Nationwide in the US

Hanmi Pharm Rolbedon. [Photo by Hanmi Pharm]

[Asia Economy Reporter Lee Gwanju] Hanmi Pharmaceutical announced on the 25th that Rolvedon (Korean product name Rollontis), a long-acting biosimilar drug for the treatment of neutropenia recently approved by the U.S. Food and Drug Administration (FDA), has been launched nationwide in the United States.

Rolvedon is a biosimilar drug used for the treatment or prevention of severe neutropenia occurring in cancer patients who have undergone chemotherapy. It applies Hanmi Pharmaceutical's proprietary platform technology ‘Lapscovery,’ which dramatically enhances the efficacy of biopharmaceuticals.

It is the first product developed by Hanmi Pharmaceutical to receive FDA marketing approval and the first new drug produced at the Korean factory (Pyeongtaek Bio Plant), which passed the FDA inspection, to be sold in the U.S. market.

Tom Riga, president of Spectrum, the U.S. partner company, said, “We are pleased to launch Rolvedon in the U.S. neutropenia treatment market worth 3 trillion won. Large quantities of the product have been delivered to our partners responsible for distribution across the United States, and we are fully prepared to achieve results in this promising market.”

Sechang Kwon, CEO of Hanmi Pharmaceutical, said, “We will focus all our capabilities to support Spectrum so that Rolvedon, which is making a full-scale entry into the U.S. market, can achieve good results locally. We will accelerate development so that Hanmi Pharmaceutical can introduce more innovative new drugs currently in global clinical trials to the U.S. market.”

This content was produced with the assistance of AI translation services.